Selected article for: "additional information and liver disease"
Author: Martínez-Urbistondo, Diego; de la Garza, Rocío G.; Villares-Fernández, Paula; Font, Carme; Schellong, Sebastian; López-Núñez, Juan José; Gil-Díaz, Aída; del Carmen Díaz-Pedroche, María; Hirmerova, Jana; Monreal, Manuel
Title: Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism
  • Cord-id: dcgqwps8
  • Document date: 2021_10_9
    • ID: dcgqwps8
    Snippet: The association between elevated liver enzymes or FIB-4 (fibrosis index 4) and outcome in patients with venous thromboembolism (VTE) has not been evaluated. Data from patients in RIETE (Registro Informatizado Enfermedad TromboEmbólica) were used to assess the association between elevated liver enzymes or FIB-4 levels and the rates of major bleeding or death in apparent liver disease-free patients with acute VTE under anticoagulation therapy. A total of 6206 patients with acute VTE and without l
    Document: The association between elevated liver enzymes or FIB-4 (fibrosis index 4) and outcome in patients with venous thromboembolism (VTE) has not been evaluated. Data from patients in RIETE (Registro Informatizado Enfermedad TromboEmbólica) were used to assess the association between elevated liver enzymes or FIB-4 levels and the rates of major bleeding or death in apparent liver disease-free patients with acute VTE under anticoagulation therapy. A total of 6206 patients with acute VTE and without liver disease were included. Of them, 92 patients had major bleeding and 168 died under anticoagulation therapy. On multivariable analysis, patients with elevated liver enzymes were at increased mortality risk (HR: 1.58; 95% CI: 1.10–2.28), while those with FIB-4 levels > 2.67 points were at increased risk for major bleeding (HR: 1.69; 95% CI: 1.04–2.74). Evaluation of liver enzymes and FIB-4 index at baseline in liver disease-free patients with VTE may provide additional information on the risk for major bleeding or death during anticoagulation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11739-021-02858-x.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute thromboembolic: 1, 2
    • absence presence and acute thromboembolic event: 1
    • absence presence and additional model: 1
    • absence presence and liver cirrhosis: 1, 2, 3, 4, 5
    • absence presence and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • absence presence and liver enzyme: 1, 2, 3
    • absence presence and liver fibrosis: 1
    • absence presence and liver inflammation: 1, 2
    • absence presence and liver status: 1
    • absence presence and long term therapy: 1
    • absence presence and low molecular weight: 1, 2, 3
    • absence presence and low molecular weight heparin: 1
    • absence presence and low probability: 1, 2, 3, 4, 5, 6
    • absence presence and low specificity: 1, 2
    • absence presence and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • absence presence and lung disease chronic heart: 1
    • acute setting and liver disease: 1, 2, 3, 4, 5
    • acute setting and liver enzyme: 1
    • acute setting and liver status: 1